#United States #Sarasota #Lakewood-Amedex #Diabetic Ulcers #Nu-3

Lakewood-Amedex Biotherapeutics Takes a Significant Step Forward in Clinical Trials

Lakewood-Amedex Biotherapeutics Inc. (NASDAQ: LABT) has reached a major milestone by enrolling its first patient in the Phase 2a clinical trial for Nu-3, an innovative treatment specifically designed for individuals suffering from mildly infected diabetic foot ulcers (iDFU). This development is not only significant for the patients involved but also underscores the company's commitment to advancing its proprietary Bisphosphocin® antimicrobial platform.

The initiation of patient dosing with Nu-3 marks a critical point in its clinical pathway, as this novel topical antimicrobial gel aims to actively eliminate bacteria directly at the infection site. One of the chief goals of the Phase 2a study is to assess the safety and effectiveness of varying gel concentrations—2%, 5%, and 10%—to guide further development plans and dosage determinations. Results from this trial are eagerly anticipated, with topline data expected in early 2027.

Understanding the Challenge of Diabetic Foot Ulcers

Diabetic foot ulcers represent a persistent problem for individuals with diabetes, leading to severe complications if left untreated. According to experts, millions around the globe grapple with these wounds, which not only incur substantial human suffering but also impose significant healthcare costs. The necessity for effective treatment options is more urgent than ever, particularly in light of the growing issue of antimicrobial resistance (AMR).

Dr. Thomas Balzer, Chief Medical Officer and Senior Vice President of Clinical Development at Lakewood-Amedex, stressed the company’s pivotal role in addressing this ongoing health crisis. “Dosing the first patient in this Phase 2a trial is a testament to our efforts in developing Nu-3 as a viable new solution for infected diabetic foot ulcers,” he stated. Nu-3's ability to mitigate common shortcomings of standard treatments—specifically concerning AMR—positions it as a favorable candidate in the therapeutic landscape.

A Comprehensive Clinical Approach

The multicenter, single-blinded nature of the Phase 2a trial enables investigators to probe deeper into Nu-3's clinical capabilities. Alongside its efficacy in reducing microbial load, the trial will examine vital safety aspects associated with the gel. The study welcomes participants with Type 1 or Type 2 diabetes, signaling an inclusive approach by the research team.

Looking ahead, the findings from this trial could set the groundwork for the subsequent Phase 2b study, where researchers will further evaluate different dosing regimens of Nu-3 against placebo controls. This ongoing exploration by Lakewood-Amedex reflects a broader initiative to tackle diabetic foot complications and improve the overall quality of life for patients.

Dr. David G. Armstrong, a renowned podiatric scholar and the study chair of the trial, echoed the sentiment of urgency for innovative treatments during the study announcement. “We continue to require new strategies that effectively manage infections,” he commented. “Advancing a locally applied topical solution like Nu-3 provides an exciting avenue to enhance how we approach these challenging infections.”

Collaboration for Success

To ensure the success of this trial, Lakewood-Amedex has partnered with the Professional Education and Research Institute LLC (PERI), a respected entity in the field of wound care research. Led by expert podiatrist Charles Zelen, PERI’s network and understanding of the diabetic foot care community are anticipated to play a fundamental role in achieving efficient patient recruitment and robust data collection.

In conclusion, the Phase 2a trial of Nu-3 signifies a positive stride in biochemical innovation, ideally harnessing advanced antimicrobial properties to positively influence patient outcomes in diabetic foot care. Lakewood-Amedex's commitment to research not only represents a beacon of hope for affected individuals but may pave the way for future breakthroughs in the ongoing battle against infections characterized by antimicrobial resistance. As this pivotal trial unfolds, the global healthcare community watches with expectation and hope for the findings that may redefine treatment methodologies for diabetic foot ulcers.

For more information about Lakewood-Amedex and its promising initiatives, visit Lakewood-Amedex.